Skip to content

Comparison of the Analgesic Efficacy of Oxycodone versus Remifentanil in Mechanically Ventilated ICU Patients

Comparison of the Analgesic Efficacy of Oxycodone versus Remifentanil in Mechanically Ventilated ICU Patients

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2500110431
Enrollment
Unknown
Registered
2025-10-14
Start date
2025-10-30
Completion date
Unknown
Last updated
2025-10-20

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Pain

Interventions

Comparator group:Remifentanil and Propofol
Study group:Oxycodone and Propofol

Sponsors

Rugao People's Hospital
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 85 Years

Inclusion criteria

Inclusion criteria: 1. Age between 18 and 85 years, inclusive. 2. Body Mass Index (BMI) greater than 18 kg/m² and less than 30 kg/m². 3. Admitted to the ICU with an anticipated requirement for mechanical ventilation >= 24 hours. 4. Hemodynamically stable.

Exclusion criteria

Exclusion criteria: 1. History of allergy to opioids. 2. Long-term use of analgesic medications. 3. Neuropsychiatric disorders requiring pharmacological treatment. 4. Combined with traumatic brain injury and/or cerebrovascular accident. 5. Treatment with neuromuscular blocking agents. 6. Cognitive impairment. 7. Brain death or vegetative state. 8. Pregnancy. 9. Participation in another clinical trial within the previous 30 days. 10. Abnormal liver or renal function (Aspartate Aminotransferase (AST) and/or Alanine Aminotransferase (ALT) and/or Total Bilirubin (TBiL) >= 2 × Upper Limit of Normal (ULN); Serum Creatinine (Cr) >= 2 × ULN, or patients requiring renal replacement therapy). 11. History of drug abuse and/or alcohol abuse within the recent 3 months. Alcohol abuse is defined as an average daily intake of > 2 standard alcohol units (1 unit = 360 mL of beer [5% alcohol] or 45 mL of spirits [40% alcohol] or 150 mL of wine).

Design outcomes

Primary

MeasureTime frame
The difference in the time to achieve ideal analgesic and sedative effects after mechanical ventilation and the total dosage of analgesics and sedatives used.;

Secondary

MeasureTime frame
Differences in propofol dose between groups;Differences in awakening time between groups after implementing daily wake-up following discontinuation of analgesics and sedatives;Differences in hemodynamic changes and vasoactive drug usage;CPOT (Critical-Care Pain Observation Tool) scores;RASS (Richmond Agitation-Sedation Scale) scores;SMH scores ;Total duration of mechanical ventilation;Length of ICU stay and total hospital stay;Incidence of adverse events such as delirium;

Countries

China

Contacts

Public ContactZhang Juan

Rugao People's Hospital

rgrmyyzj@163.com+86 139 2168 9256

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026